Vés al contingut

A 52-week randomized,double-blind, placebocontrolled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L antagonist monoclonal antibody, for preservation of pancreatic ß-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

Obert
  • Codi protocol: DRI17476
  • Codi EudraCT: No aplica
  • Grup de recerca: Diabetis i Metabolisme
  • Servei: Endocrinologia
  • Investigador/a principal:  Hernández Pascual, Cristina
  • Malaltia: Malalties endocrines, nutricionals i metabòliques
  • Fase: Fase II